Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes

被引:126
作者
Ruggiero, Alessandro [1 ,2 ]
Villa, Carlos H. [1 ,2 ]
Holland, Jason P. [1 ,2 ]
Sprinkle, Shanna R. [1 ,2 ]
May, Chad [3 ]
Lewis, Jason S. [1 ,2 ]
Scheinberg, David A. [1 ,2 ]
McDevitt, Michael R. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med & Radiol, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pharmacol & Mol Therapeut, New York, NY 10065 USA
[3] ImClone Syst, New York, NY USA
基金
美国国家卫生研究院;
关键词
actinium-225 (Ac-225); zirconium-89 (Zr-89); angiogenesis; vascular endothelial-cadherin; radioimmunotherapy (RIT); radioimmunoPET; CANCER STEM-CELLS; ENDOTHELIAL-CADHERIN; PERIVASCULAR NICHE; ATOMIC GENERATOR; ANGIOGENESIS; THERAPY; RADIOIMMUNOTHERAPY; ANTIBODY; GROWTH; PHARMACOKINETICS;
D O I
10.2147/IJN.S13300
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Single wall carbon nanotube (SWCNT) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA] or desferrioxamine B [DFO]) and the tumor neovascular-targeting antibody E4G10. The E4G10 antibody specifically targeted the monomeric vascular endothelial-cadherin (VE-cad) epitope expressed in the tumor angiogenic vessels. The construct specific activity and blood compartment clearance kinetics were significantly improved relative to corresponding antibody-alone constructs. We performed targeted radioimmunotherapy with a SWCNT-([Ac-225]DOTA) (E4G10) construct directed at the tumor vasculature in a murine xenograft model of human colon adenocarcinoma (LS174T). The specific construct reduced tumor volume and improved median survival relative to controls. We also performed positron emission tomographic (PET) radioimmunoimaging of the tumor vessels with a SWCNT-([Zr-89]DFO)(E4G10) construct in the same murine LS174T xenograft model and compared the results to appropriate controls. Dynamic and longitudinal PET imaging of LS174T tumor-bearing mice demonstrated rapid blood clearance (, 1 hour) and specific tumor accumulation of the specific construct. Incorporation of the SWCNT scaffold into the construct design permitted us to amplify the specific activity to improve the signal-to-noise ratio without detrimentally impacting the immunoreactivity of the targeting antibody moiety. Furthermore, we were able to exploit the SWCNT pharmacokinetic (PK) profile to favorably alter the blood clearance and provide an advantage for rapid imaging. Near-infrared three-dimensional fluorescent-mediated tomography was used to image the LS174T tumor model, collect antibody-alone PK data, and calculate the number of copies of VE-cad epitope per cell. All of these studies were performed as a single administration of construct and were found to be safe and well tolerated by the murine model. These data have implications that support further imaging and radiotherapy studies using a SWCNT- based platform and focusing on the tumor vessels as the target.
引用
收藏
页码:783 / 802
页数:20
相关论文
共 72 条
[1]   Biodegradation of Single-Walled Carbon Nanotubes through Enzymatic Catalysis [J].
Allen, Brett L. ;
Kichambare, Padmakar D. ;
Gou, Pingping ;
Vlasova, Irina I. ;
Kapralov, Alexander A. ;
Konduru, Nagarjun ;
Kagan, Valerian E. ;
Star, Alexander .
NANO LETTERS, 2008, 8 (11) :3899-3903
[2]   Mechanistic Investigations of Horseradish Peroxidase-Catalyzed Degradation of Single-Walled Carbon Nanotubes [J].
Allen, Brett L. ;
Kotchey, Gregg P. ;
Chen, Yanan ;
Yanamala, Naveena V. K. ;
Klein-Seetharaman, Judith ;
Kagan, Valerian E. ;
Star, Alexander .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (47) :17194-17205
[3]   Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids:: Efficacy versus HER2/neu expression [J].
Ballangrud, ÅM ;
Yang, WH ;
Palm, S ;
Enmon, R ;
Borchardt, PE ;
Pellegrini, VA ;
McDevitt, MR ;
Scheinberg, DA ;
Sgouros, G .
CLINICAL CANCER RESEARCH, 2004, 10 (13) :4489-4497
[4]   Plasmalemmal concentration and affinity of mouse vascular endothelial cadherin, VE-cadherin [J].
Baumgartner, W ;
Drenckhahn, D .
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2002, 31 (07) :532-538
[5]  
Borchardt PE, 2003, CANCER RES, V63, P5084
[6]   VASCULAR TARGETING - A NEW APPROACH TO THE THERAPY OF SOLID TUMORS [J].
BURROWS, FJ ;
THORPE, PE .
PHARMACOLOGY & THERAPEUTICS, 1994, 64 (01) :155-174
[7]   Multimodality molecular imaging of tumor angiogenesis [J].
Cai, Weibo ;
Chen, Xiaoyuan .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 :113S-128S
[8]   A perivascular niche for brain tumor stem cells [J].
Calabrese, Christopher ;
Poppleton, Helen ;
Kocak, Mehmet ;
Hogg, Twala L. ;
Fuller, Christine ;
Hamner, Blair ;
Oh, Eun Young ;
Gaber, M. Waleed ;
Finklestein, David ;
Allen, Meredith ;
Frank, Adrian ;
Bayazitov, Ildar T. ;
Zakharenko, Stanislav S. ;
Gajjar, Amar ;
Davidoff, Andrew ;
Gilbertson, Richard J. .
CANCER CELL, 2007, 11 (01) :69-82
[9]   A monoclonal antibody to vascular endothehal-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability [J].
Corada, M ;
Zanetta, L ;
Orsenigo, F ;
Breviario, F ;
Lampugnani, MG ;
Bernasconi, S ;
Liao, F ;
Hicklin, DJ ;
Bohlen, P ;
Dejana, E .
BLOOD, 2002, 100 (03) :905-911
[10]   Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability [J].
Corada, M ;
Liao, F ;
Lindgren, M ;
Lampugnani, MG ;
Breviario, F ;
Frank, R ;
Muller, WA ;
Hicklin, DJ ;
Bohlen, P ;
Dejana, E .
BLOOD, 2001, 97 (06) :1679-1684